Drug Approval | April 08, 2026
Lupin wins USFDA nod for generic Dapagliflozin tablets
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
The center combines rigorous scientific instruction with practical, hands-on training, equipping providers with the clinical, consultative, and business skills needed to deliver safe, effective, and patient-centered care
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
The trial also demonstrated significant improvements across multiple secondary endpoints
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
The collaboration promises expanded funding for Thai universities, research institutes, companies, and global research partners working in Thailand
Immediate opportunity in the $10.2 billion U.S. market as the diabetes therapy will be manufactured at Zydus’ SEZ Ahmedabad facility
New filtration lines will boost global drug supply and strengthen India’s role in Merck’s manufacturing network
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Recognition across subsidiaries and geographies highlights pharma major’s focus on inclusive culture, employee experience, and global workforce development
Subscribe To Our Newsletter & Stay Updated
